Revopsis Therapeutics

RevOpsis Therapeutics is a next-generation biopharmaceutical company that is trailblazing a new era in multispecific antibody discovery and development to unlock transformative treatments for complex disease. Our process is simple. Our proprietary Rev-Mod Platform uses a modular plug-and-play system to streamline drug discovery and development. The Rev-Mod Platform features a library of ~30 billion fully human and fully compatible antibody components that are ready to be assembled into functional Multi-Mod biologics. Using this platform, we can select and integrate multiple antibody components into a single, multispecific therapeutic molecule that binds targets implicated in known, clinically validated disease pathways. Our lead asset from this platform, RO-104, is a first-in-class trispecific biologic. RO-104 targets 3 clinically validated pathways that are implicated in retinal vascular diseases, such as neovascular age-related macular degeneration (nAMD). Whereas current anti-VEGF therapies used to treat nAMD predominantly target only the VEGF-A pathway, RO-104 builds on a body of literature that suggests that combining the targeting of VEGF-A, VEGF-C, and Ang-2 can improve patients’ therapeutic gains and extend treatment durability. RO-104 has the potential to offer these benefits with a single therapeutic molecule, as preclinical studies indicate high affinity to all 3 targets, efficacy in a choroidal neovascularization model, and ideal drug-like properties.